Aslan Pharmaceuticals Correlations
| ASLNDelisted Stock | USD 0.60 0.03 4.76% |
The current 90-days correlation between Aslan Pharmaceuticals and NewAmsterdam Pharma is 0.32 (i.e., Weak diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Aslan Pharmaceuticals Correlation With Market
Good diversification
The correlation between Aslan Pharmaceuticals and DJI is -0.05 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aslan Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Aslan |
Moving together with Aslan Stock
| 0.76 | TCHH | Trustcash Holdings | PairCorr |
| 0.7 | SHG | Shinhan Financial | PairCorr |
| 0.7 | EC | Ecopetrol SA ADR | PairCorr |
| 0.79 | HYMTF | Hyundai Motor | PairCorr |
| 0.74 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.63 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.8 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.76 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.76 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Aslan Stock
| 0.89 | WMT | Walmart Aggressive Push | PairCorr |
| 0.83 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.77 | JPM | JPMorgan Chase Sell-off Trend | PairCorr |
| 0.76 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.76 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.75 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.74 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.69 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.62 | HPQ | HP Inc | PairCorr |
| 0.46 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.44 | KB | KB Financial Group | PairCorr |
| 0.43 | VFS | VinFast Auto | PairCorr |
| 0.38 | KEP | Korea Electric Power | PairCorr |
| 0.32 | XOM | Exxon Mobil Corp Fiscal Year End 7th of February 2025 | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Aslan Stock performing well and Aslan Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aslan Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | 5.10 | 0.59 | 0.18 | 0.31 | 3.88 | 8.10 | 102.66 | |||
| NAMS | 2.34 | 0.18 | 0.09 | 0.20 | 3.31 | 5.33 | 29.23 | |||
| IVA | 3.35 | 0.30 | 0.05 | 1.09 | 4.09 | 7.26 | 49.76 | |||
| CGEM | 2.87 | (0.46) | 0.00 | 2.44 | 0.00 | 5.88 | 17.85 | |||
| CMPX | 4.18 | 0.02 | 0.06 | 0.12 | 4.50 | 11.19 | 29.38 | |||
| GPCR | 2.96 | (0.25) | 0.00 | (0.23) | 0.00 | 8.18 | 24.50 | |||
| IOBT | 5.27 | (1.11) | 0.00 | (0.28) | 0.00 | 7.48 | 69.64 | |||
| ERAS | 3.33 | (0.16) | (0.01) | 0.04 | 3.66 | 7.34 | 17.38 | |||
| LYRA | 4.16 | (0.60) | 0.00 | (0.98) | 0.00 | 8.00 | 41.07 | |||
| ANEB | 5.13 | (0.43) | 0.00 | (0.16) | 0.00 | 8.61 | 76.00 |
View Aslan Pharmaceuticals Related Equities
| Risk & Return | Correlation |
Aslan Pharmaceuticals Corporate Management
| Alexandre MD | Chief Officer | Profile | |
| Stephen Doyle | Chief Officer | Profile | |
| Charlie Hsu | Investor Director | Profile | |
| ChiChin Wang | IR Director | Profile | |
| Ben Goodger | General Counsel | Profile | |
| Carl EMBA | CEO Founder | Profile |
Still Interested in Aslan Pharmaceuticals?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.